Estrella Immunopharma, Inc.
ESLA$42M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaEMERYVILLE
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 31, 2026
41wMarket Overview
Stock performance and key metrics
ESLA News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EB103 | Phase 2 | B-Cell Non-Hodgkin's Lymphoma (NHL) | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply